MedTrace Logo

Proof of Concept Study of AX-158 in Patients With Mild to Moderate Plaque Psoriasis

NCT05725057 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2025-10-03

No results posted yet for this study

Summary

Proof of concept study to assess the safety and tolerability of AX-158 in patients with mild to moderate psoriasis. Patients will be evaluated for a 28-day treatment period with either AX-158 or Placebo and then followed for an additional 30 days for safety.

Conditions

Interventions

DRUG

AX-158

Subjects randomized to this arm will receive AX-158 treatment for 28 days with a 30 day safety follow-up period.

DRUG

Placebo

Subjects randomized to this arm will receive placebo treatment for 28 days with a 30 day safety follow-up period.

Sponsors & Collaborators

  • Artax Biopharma Inc

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-30
Primary Completion
2024-09-04
Completion
2024-10-04

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05725057 on ClinicalTrials.gov